Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Quoted Executive Changes Commercial

QUOTED. May 14, 2018. Omar Ishrak.

  • News

Executive Summary

Company stock will make up the "vast majority" of Mike Weinstein's compensation for being Medtronic's new senior VP of strategy. CEO Omar Ishrak said Medtronic's evolving executive compensation policies are an element of the firm's efforts to improve value to shareholders. See what Ishrak said about it here.

"We have changed our executive compensation fairly deep in our organization to reflect the sense of urgency we have about creating free cash flow. Executive compensation does drive behavior, does drive priorities and clarifies those priorities. And Mike choosing to be paid largely in Medtronic stock is a big signal as to what we can do and the confidence we have with respect to shareholder value." –Omar Ishrak, CEO, Medtronic

Click here for a free trial of Medtech Insight

Table

View full table

Related Content

Medtech Insight

Topics

Tags:
Quoted Executive Changes Commercial
Latest Headlines

It’s Been Over 1100 Days Since MCIT, Still No TCET In Sight

Mini-Slings Are Comparable To Traditional Ones To Treat Incontinence, FDA Says

Ekso's Exoskeleton Receives Medicare Coverage, Paves Way To Faster Rehabilitation

EU Regulatory Experts Support Notified Bodies, But Argue For Greater Consistency

See All
UsernamePublicRestriction

Register

MT122661

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By